Northern Trust
XENE icon

Northern Trust’s Xenon Pharmaceuticals XENE Stock Holding History

Northern Trust’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.7M Buy
527,783
+89,069
+20% +$4.1M ﹤0.01% 1421
2025
Q4 		$19.7M Sell
438,714
-59,433
-12% -$2.5M ﹤0.01% 1664
2025
Q3 		$20M Buy
498,147
+8,207
+2% +$289K ﹤0.01% 1682
2025
Q2 		$15.3M Buy
489,940
+408,916
+505% +$13.3M ﹤0.01% 1818
2025
Q1 		$2.72M Buy
81,024
+15,241
+23% +$579K ﹤0.01% 2756
2024
Q4 		$2.58M Buy
65,783
+22,377
+52% +$925K ﹤0.01% 2878
2024
Q3 		$1.71M Sell
43,406
-3,446
-7% -$139K ﹤0.01% 3095
2024
Q2 		$1.83M Sell
46,852
-1,618
-3% -$64.7K ﹤0.01% 2943
2024
Q1 		$2.09M Sell
48,470
-13,501
-22% -$621K ﹤0.01% 2932
2023
Q4 		$2.85M Sell
61,971
-7,196
-10% -$254K ﹤0.01% 2804
2023
Q3 		$2.36M Buy
69,167
+3,684
+6% +$138K ﹤0.01% 2848
2023
Q2 		$2.52M Buy
65,483
+4,480
+7% +$178K ﹤0.01% 2877
2023
Q1 		$2.18M Buy
61,003
+786
+1% +$29K ﹤0.01% 2902
2022
Q4 		$2.37M Buy
60,217
+9,326
+18% +$340K ﹤0.01% 2906
2022
Q3 		$1.84M Buy
50,891
+2,895
+6% +$104K ﹤0.01% 3050
2022
Q2 		$1.46M Buy
47,996
+3,220
+7% +$97.4K ﹤0.01% 3219
2022
Q1 		$1.37M Sell
44,776
-5,820
-12% -$174K ﹤0.01% 3278
2021
Q4 		$1.58M Buy
50,596
+12,746
+34% +$381K ﹤0.01% 3339
2021
Q3 		$579K Sell
37,850
-6,871
-15% -$119K ﹤0.01% 3717
2021
Q2 		$832K Sell
44,721
-5,841
-12% -$108K ﹤0.01% 3575
2021
Q1 		$904K Buy
50,562
+3,940
+8% +$66.8K ﹤0.01% 3624
2020
Q4 		$717K Sell
46,622
-15,731
-25% -$184K ﹤0.01% 3627
2020
Q3 		$690K Buy
62,353
+718
+1% +$8.45K ﹤0.01% 3528
2020
Q2 		$772K Buy
61,635
+3,036
+5% +$38.6K ﹤0.01% 3435
2020
Q1 		$664K Buy
58,599
+14,456
+33% +$206K ﹤0.01% 3371
2019
Q4 		$579K Buy
44,143
+6,507
+17% +$68.4K ﹤0.01% 3523
2019
Q3 		$339K Hold
37,636
– – ﹤0.01% 3632
2019
Q2 		$371K Buy
37,636
+13,434
+56% +$129K ﹤0.01% 3637
2019
Q1 		$246K Buy
24,202
+11,956
+98% +$101K ﹤0.01% 3723
2018
Q4 		$77K Buy
12,246
+1,948
+19% +$17.3K ﹤0.01% 3973
2018
Q3 		$136K Buy
+10,298
New +$119K ﹤0.01% 3961

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust's XENE Position: Q1 2026 in Review

Northern Trust increased its Xenon Pharmaceuticals (XENE) stake by 20% in Q1 2026, buying an estimated $4.1M and bringing the position to 527,783 shares worth $30.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

Northern Trust first reported a position in XENE in Q3 2018 and has held it in 31 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Northern Trust held 527,783 shares of Xenon Pharmaceuticals worth $30.7M as of Q1 2026.
  • Northern Trust bought 89,069 Xenon Pharmaceuticals shares in Q1 2026, an estimated $4.1M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1421 holding.
  • Northern Trust first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.